Cardiac Dimensions
Cardiac Dimensions is a privately held medical device company that develops the Carillon Mitral Contour System, a catheter-based transcatheter mitral valve repair device for treating functional mitral regurgitation in heart failure patients, sold to hospital cardiac catheterization labs in Europe and Australia with U.S. approval pending.
- Company typePrivate
- Founded2001
- HeadquartersKirkland, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cardiac Dimensions does
Cardiac Dimensions is a privately held medical device company founded in 2001 that develops the Carillon Mitral Contour System, a catheter-based transcatheter device intended to treat functional mitral regurgitation (FMR) in heart failure patients via an indirect mitral annuloplasty approach through the coronary sinus. The device uses distal and proximal anchors connected by a shaping ribbon to cinch the mitral valve apparatus without damaging the leaflets, inducing favorable left ventricular remodeling and preserving access to future therapies including cardiac resynchronization. The company is headquartered in Kirkland, Washington, with operational offices in Sydney, Australia and Frankfurt, Germany, and operates with roughly 65 employees. Its core customer is the hospital cardiac catheterization laboratory performing transcatheter mitral valve procedures, with primary end-patients being heart failure patients with reduced or preserved ejection fraction and FMR grades 2+ through 4+.
Cardiac Dimensions generates revenue through direct hardware sales of the Carillon system to hospitals, with full reimbursement in key European markets (notably Germany under DRG) and TGA-approved commercial sales in Australia. The U.S. market is investigational-only, with the device limited to use in the EMPOWER randomized sham-controlled pivotal trial designed to support FDA approval. The company has treated over 1,500 patients cumulatively, holds 30+ US patents, and possesses the most comprehensive longitudinal clinical evidence base in the indirect annuloplasty category, including 5-year multi-center registry data, 10-year survival data, and inclusion in 2021 European Society of Cardiology Guidelines as the first non-TEER device recommended for secondary mitral regurgitation. Over $200 million in total venture funding has been raised across multiple rounds, with the most recent $53 million Series E in March 2025 earmarked to complete the EMPOWER pivotal study and support global commercialization.
Cardiac Dimensions firmographics
Firmographics- Name
- Cardiac Dimensions
- Legal name
- Cardiac Dimensions Pty. Ltd.
- Website
- https://cardiacdimensions.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cardiac Dimensions is a privately held medical device company that develops the Carillon Mitral Contour System, a catheter-based transcatheter mitral valve repair device for treating functional mitral regurgitation in heart failure patients, sold to hospital cardiac catheterization labs in Europe and Australia with U.S. approval pending.
- Ownership category
- akta.pro rank
Cardiac Dimensions industry classification
Industry- Product category
- Transcatheter Mitral Valve Repair Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
- akta.pro secondary industries
- Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB), Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)
Keywords
Where Cardiac Dimensions is headquartered
LocationHeadquarters
- HQ city
- Kirkland
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Cardiac Dimensions business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel
Revenue model
- Carillon Mitral Contour System Sales: Sale of the Carillon Mitral Contour System, a catheter-based medical device for treating functional mitral regurgitation in heart failure patients. The device is commercially available in Europe and other countries following CE Mark clearance, and is investigational in the U.S. pending FDA approval.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Cardiac Dimensions product offering
Product offeringCore offering
Cardiac Dimensions develops and commercializes the Carillon Mitral Contour System, a catheter-based, minimally invasive device designed to treat functional mitral regurgitation (FMR) in heart failure patients. The device is delivered percutaneously via the coronary sinus and uses distal and proximal anchors connected by a shaping ribbon to reshape the mitral valve apparatus without damaging valve leaflets. It is sold directly to hospitals and cardiac catheterization labs in Europe and Australia, while U.S. use is limited to investigational settings via the EMPOWER pivotal trial.
Product overview
Cardiac Dimensions offers a single flagship product, the Carillon Mitral Contour System, a catheter-based minimally invasive device designed to treat functional mitral regurgitation (FMR) in heart failure patients. The system uses a transcatheter approach via the coronary sinus with distal and proximal anchors connected by a shaping ribbon. The device is CE Marked and commercially available in Europe and other countries that recognize CE Mark, TGA approved in Australia, and is currently under investigation in the U.S. pivotal EMPOWER Trial for FDA approval.
Differentiator
Problem solved
Functional benefit
Brands
- Carillon Mitral Contour System: Catheter-based transcatheter indirect mitral annuloplasty device designed to treat functional mitral regurgitation by reshaping the mitral valve apparatus via the coronary sinus. The only commercially available indirect mitral annuloplasty device.
- Carillon
- EMPOWER Trial
Products and services
- Carillon Mitral Contour System A catheter-based, minimally invasive transcatheter indirect mitral annuloplasty device that reshapes the mitral valve apparatus via the coronary sinus using distal and proximal anchors connected by a shaping ribbon. Designed for heart failure patients with functional mitral regurgitation (FMR) grades 2+ to 4+. CE Marked, MDR certified, and TGA approved; under U.S. EMPOWER pivotal trial for FDA approval.
Quantifiable outcome
- 97% of patients maintained stable or improved MR grade across all time points through five years
- +6 more outcomes
Companies that use Cardiac Dimensions
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles1 record
Cardiac Dimensions technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Cardiac Dimensions partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Qtis.aicoreQtis.ai launched its AI-native Clinical Trial Management System (CTMS) with Cardiac Dimensions as the first commercial customer. Cardiac Dimensions will use Qtis.ai's platform for clinical trial management including document management and integrated research operations.
- Cleveland CliniccoreLeading center participating in the EMPOWER pivotal trial. Dr. Samir Kapadia serves as national principal investigator for the trial.
- Columbia University Medical CentercoreLeading center participating in the EMPOWER pivotal trial for U.S. regulatory approval.
- Ronald Reagan UCLA Medical CentercoreLeading center participating in the EMPOWER pivotal trial for U.S. regulatory approval.
- European Society of CardiologycoreESC Guidelines published recommendations supporting the Carillon Mitral Contour System for treatment of secondary mitral regurgitation. First non-TEER device included in heart failure guidelines.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
Cardiac Dimensions competitors and assessment
Company assessmentEmerging players
- Corvia Medical: Corvia Medical develops the Corvia Atrial Shunt (IASD) for heart failure with preserved ejection fraction (HFpEF). It targets an overlapping heart failure patient population through a different interventional mechanism, sharing potential referral channels and clinical thought leaders.
- Ancora Heart: Ancora Heart is developing the AccuCinch ventricular restoration system for heart failure patients with functional mitral regurgitation. It is an emerging player addressing an overlapping patient population via a different mechanism (ventricular reshaping rather than annular).
- Polares Medical: Polares Medical is developing a transcatheter mitral valve replacement (TMVR) technology targeting functional mitral regurgitation. It is an emerging structural heart company in the same clinical space with a complementary therapeutic approach.
- NeoChord: NeoChord develops transcatheter chordal repair technology for degenerative mitral regurgitation using a transapical approach. It is an emerging player in the minimally invasive mitral valve repair space with a different but adjacent technology approach.
- Valcare Medical: Valcare Medical is developing transcatheter mitral and tricuspid valve repair and replacement technologies. It is an emerging Israeli medical device company focused on structural heart interventions with overlapping therapeutic goals.
- V-Wave Ltd. V-Wave is developing interatrial shunts for heart failure with preserved and reduced ejection fraction. While targeting a different mechanism, both companies address the same heart failure population and have overlapping clinical and commercial channels.
Broad incumbents
- Medtronic: Medtronic is developing the Intrepid transcatheter mitral valve replacement (TMVR) system and has broader structural heart portfolio including the Intrepid, Evolut, and Harmony platforms. It is a broad incumbent in cardiovascular devices with overlapping mitral valve treatment ambitions.
- Boston Scientific: Boston Scientific has a structural heart portfolio and has invested in transcatheter mitral and tricuspid valve technologies through acquisitions and partnerships. It competes in the broader cardiovascular space with relevant mitral valve repair and replacement programs.
Direct peers
- Edwards Lifesciences: Edwards Lifesciences markets the PASCAL transcatheter valve repair system for mitral regurgitation, directly competing with both Carillon and MitraClip. The company is a major structural heart player with overlapping catheter-based mitral valve repair technology.
- Abbott: Abbott markets the MitraClip, the leading transcatheter edge-to-edge repair (TEER) device for mitral regurgitation. It is the most commercially successful transcatheter mitral valve repair product and the primary direct competitor to Cardiac Dimensions' Carillon system for treating functional mitral regurgitation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cardiac Dimensions social profiles
Digital presenceCardiac Dimensions compliance and trust
Trust signalCompliance4 records
Cardiac Dimensions financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cardiac Dimensions leadership team
Management profileNumber of profiles
Profiles9 records
Cardiac Dimensions subsidiaries and ownership
Company hierarchySubsidiaries1 record
Cardiac Dimensions funding detail
Funding detailFunding overview
Funding rounds11 records
Investors24 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cardiac Dimensions M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cardiac Dimensions
What does Cardiac Dimensions do?
Cardiac Dimensions develops and commercializes the Carillon Mitral Contour System, a catheter-based, minimally invasive device designed to treat functional mitral regurgitation (FMR) in heart failure patients. The device is delivered percutaneously via the coronary sinus and uses distal and proximal anchors connected by a shaping ribbon to reshape the mitral valve apparatus without damaging valve leaflets. It is sold directly to hospitals and cardiac catheterization labs in Europe and Australia, while U.S. use is limited to investigational settings via the EMPOWER pivotal trial.
Is Cardiac Dimensions a public or private company?
Cardiac Dimensions is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cardiac Dimensions founded?
Cardiac Dimensions was founded in 2001. It employs 51 to 100 people.
Where is Cardiac Dimensions based?
Cardiac Dimensions is headquartered in Kirkland, United States, in the North America region.
How does Cardiac Dimensions make money?
One revenue line is on record: carillon Mitral Contour System Sales.
Who are Cardiac Dimensions's main competitors?
Emerging players on record are Corvia Medical, Ancora Heart, Polares Medical, NeoChord, Valcare Medical and V-Wave Ltd.. Broad incumbents are Medtronic and Boston Scientific. Direct peers are Edwards Lifesciences and Abbott.
Does Cardiac Dimensions have an API?
No public API is recorded for Cardiac Dimensions.
What industry is Cardiac Dimensions in?
Cardiac Dimensions's product category is Transcatheter Mitral Valve Repair Devices. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair. Its NAICS code is 334510 and its SIC code is 3841.